



The Canadian Association of Pharmacy in Oncology presents the

2005 | **National Oncology Pharmacy Symposium**
From a Patient's Perspective
Onsite Program



OCTOBER 28-30, 2005 | SHERATON WALL CENTRE | VANCOUVER, BRITISH COLUMBIA



2005 | PLATINUM SPONSORS



2005 | GOLD SPONSORS



2005 | SILVER SPONSORS



2005 | BRONZE SPONSORS





2005 | Message from the Co-Chairs and Message du Comité Organisateur

On behalf of the conference organising committee, it is our pleasure to welcome you, the oncology pharmacists, to CAPHO's annual cancer conference – the National Oncology Pharmacy Symposium (NOPS) 2005.

We are very excited to be hosting one of the first NOPS meetings outside of central Canada and what better place than in Vancouver and beautiful British Columbia. It is our intention to offer something useful, interesting – and perhaps enlightening – to all of you in this conference. As oncology pharmacists we are a diverse group of practitioners – from highly trained individuals who ply their trade in specialised areas to those of us who contribute occasional but important input into the pharmaceutical care of cancer patients. We hope that you will leave this meeting with something that you can take back with you and apply to your practice. And yes, please take this great opportunity to meet and network with your colleagues across the nation.

NOPS 2005 would not be possible without the enthusiasm and dedication of the organizing committee. We have pharmacists from across the country who volunteered their time for this conference and they have been an absolute pleasure to work with. We sincerely hope that you will have a great experience over this weekend and if so, perhaps join the committee for NOPS 2006 by contacting one of us or the CAPHO executive. Finally, we would like to thank our pharmaceutical sponsors for their generous support and invite you to visit their displays on Saturday.

True knowledge, as they say, cannot be taught, and the best teachers are the students themselves. We salute all of you who have made the effort to come to NOPS 2005 for continuing education in oncology pharmacy.

Au nom du comité organisateur, c'est avec un immense plaisir que nous vous accueillons chère(s) collègues pharmacien(ne)s oeuvrant dans le domaine de l'oncologie à la conférence annuelle de l'Association Canadienne de Pharmacie en Oncologie (ACPhO) : National Oncology Pharmacy Symposium (NOPS), édition 2005.

Nous sommes heureux de vous présenter l'une des premières éditions de la conférence NOPS dans la magnifique ville de Vancouver en Colombie-Britannique. Notre objectif est de vous transmettre des connaissances utiles, enrichissantes et nouvelles. En tant que pharmacien(ne)s oeuvrant dans le domaine de l'oncologie, nous sommes appelé(e)s à participer activement au sein de divers groupes de pratique. Et c'est dans cette optique que nous espérons que vous serez en mesure d'appliquer quotidiennement les différents sujets abordés durant ce symposium. Profitez également de cette opportunité pour rencontrer et partager vos expériences avec vos collègues pharmacien(ne)s provenant de toutes les régions du Canada.

La réalisation du NOPS 2005 est possible, année après année, grâce à la collaboration, l'enthousiasme et le dévouement du comité organisateur et de ces différents membres qui y consacrent temps et énergie. Nous espérons sincèrement que l'expérience de cette fin de semaine vous sera profitable et sera ainsi source de motivation pour participer à l'organisation de l'édition 2006 du NOPS. Le cas échéant, contactez un des membres du présent comité organisateur ou du comité exécutif de l'ACPhO.

Nous tenons également à souligner la contribution de l'industrie pharmaceutique qui a permis la réalisation de ce symposium. Nous vous invitons, samedi prochain, à visiter les kiosques des compagnies participantes.

En conclusion, nous saluons les efforts de chacun d'entre vous qui êtes venus en grand nombre au NOPS 2005 pour parfaire votre éducation continue en oncologie.

Mario de Lemos
Victoria Kyritsis
Martin Franco

Co-Chairs



SCHERING CANADA INC.

Pr Temodal*
temozolomide 

*Schering Canada and
Schering-Plough Corporation*
are dedicated to investing in
cancer research both to find
new uses for our existing
drugs and to discover newer,
even more effective therapies.
We are dedicated to battling
these devastating diseases.



2005 | Message from the CAPHO Chair

CAPHO Welcome!

On behalf of the membership of the Canadian Association of Pharmacy in Oncology and the NOPS Organizing Committee, I would like to welcome you to our annual professional meeting!

This meeting marks a change for CAPHO, in that this is the first meeting to be held outside of central Canada. Last year, the CAPHO Executive approved the following meeting rotation in an effort to reach even more oncology pharmacists across the country:

*2005 Vancouver
2006 Montreal
2007 Halifax
2008 Toronto*

The NOPS Organizing Committee has, once again, done a fabulous job, putting together one of the most comprehensive educational programs we've ever had. In addition, we are pleased to welcome several of our industry partners, who are sponsoring the event and the Satellite Symposia. This meeting is your chance to meet and network with your colleagues from across the country, while at the same time learning the most up-to-date oncology pharmacy information. Your CAPHO Executive will also be on hand at the meeting to talk with you about the variety of initiatives that CAPHO has ongoing.

We hope that you will enjoy the meeting, and look forward to seeing you there!

Lynne Nakashima
CAPHO President 2003-2005

2005 | Thank you to our CAPHO Executive

<i>Lynne Nakashima</i>	<i>Susan Walisser</i>
<i>George Dranitsaris</i>	<i>Tim VanHelveert</i>
<i>Gabriel Gazze</i>	<i>John Wiernikowski</i>
<i>Dana Cole</i>	<i>Betty Riddell</i>
	<i>Kim Stefaniuk</i>

GlaxoSmithKline

Proud supporter of

**CAPHO & The National Oncology
Pharmacy Symposium**



www.gsk.ca

Do more, feel better, live longer



◆
ORTHO BIOTECH

DIVISION OF JANSSEN-ORTHO INC.

*At Ortho Biotech
we have a passion for the work we
do and compassion for the patients
and providers we serve.*

*We have dedicated our efforts
to improve patient care and
outcomes in cancer through
treatments that enhance
patients' lives.*

*We are committed to leading
the fight against serious illness
and we have engaged in
comprehensive and innovative
programs that benefit and
empower both healthcare
professionals and patients alike.*



© Ortho Biotech 2004. A Division of Janssen-Ortho Inc.
19 Green Belt Drive, Toronto, Ontario M3C 1L9
ECCA041025A 8855



2005 | Thank you to the NOPS Planning Committee Members

Venetia Bourrier
CancerCare Manitoba, Winnipeg, MB

Carole Chambers
Alberta Cancer Board, Calgary, AB

Flay Charbonneau
Sunnybrook Regional Cancer Centre, Toronto, ON

Mário de Lemos
British Columbia Cancer Agency, Vancouver, BC

Roxanne Dobish
Cross Cancer Institute Pharmacy, Edmonton, AB

Scott Edwards
Dr. H. Bliss Murphy Cancer Centre, St. John's, NL

Martin Franco
Hôpital Maisonneuve-Rosemont, Montréal, QC

Victoria Kyritsis
British Columbia Cancer Agency, Vancouver, BC

Sandy Linseman
Grand River Regional Cancer Centre, Kitchener, ON

Kimberley Stefaniuk
Princess Margaret Hospital, Toronto, ON

Pat Trozzo
CancerCare Manitoba, Winnipeg, MB

Thanh Vu
British Columbia Cancer Agency, Vancouver, BC

Susan Walisser
British Columbia Cancer Agency, Victoria, BC

**WE'RE ADVANCING ONCOLOGY
TO MEET CANCER HEAD-ON**

*You have come to rely upon our current therapies.
But at Pfizer Oncology, that's just the beginning.
Now we're looking toward the future. Our
experts are exploring thousands of newly
identified genes, proteins, and pathways that
govern cancer growth so we can develop more
resources, more discoveries, and more solutions.
Because, like you, we think it's time to
make cancer history. And we're investing
all we can to do it.*


Pfizer Oncology

From Laboratory to Living

* TM Pfizer Enterprises, SARL
Pfizer Canada Inc., licensee

© 2005
Pfizer Canada Inc.
Kirkland, Quebec
H3J 2M5

PFAB
R&D



40 years ago, there was one viable drug therapy for cancer. **Today, there are over 100. Roche has pioneered several of these treatments, giving cancer patients new hope.**



20 years ago, kidney transplants were seldom successful long term. **Now, over 90% of patients enjoy full lives after their transplant, thanks in part to innovative therapies from Roche.**



5 years ago, about 1% of human DNA had been sequenced. **Today, the complete genome is mapped. With this knowledge, Roche is working to revolutionize disease prevention and treatment.**

IT'S JUST A MATTER OF TIME.

Focused research makes miracles like these happen. At Roche, we're dedicated to trail-blazing research to create new therapies, proven diagnostics, and innovative biotechnology. Leading Canadians to a future when health threats like cancer, obesity, heart disease, stroke, and HIV truly are part of the past. Roche – Research that delivers results.


www.rochecanada.com



Registered Trade-Mark of
Hoffmann-La Roche Limited




2005 | Sheraton Wall Centre Floorplan



Listed in Alberta,
Manitoba and Quebec*

NOW AVAILABLE



Aranesp® for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies is here.

Aranesp® is indicated for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.

Aranesp® is not intended for patients who require immediate correction of severe anemia or emergency transfusions. Blood pressure should be adequately controlled prior to initiation of Aranesp® therapy and must be closely monitored and controlled during treatment. Aranesp® is not indicated for other causes of anemia such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding which should be managed appropriately.

Aranesp® is contraindicated in patients with uncontrolled hypertension, a known hypersensitivity to the active substance or any of the excipients, sensitivity to mammalian cell-derived products or albumin formulation.*

The most commonly reported adverse events in cancer patients receiving chemotherapy were fatigue (33% vs. 30% placebo), edema (21% vs. 10% placebo), fever (19% vs. 16% placebo), dizziness (14% vs. 8% placebo), constipation (18% vs. 17% placebo), diarrhea (22% vs. 12% placebo), and arthralgia (13% vs. 6% placebo). The most frequently reported serious adverse events included death (10%), fever (4%), pneumonia (3%), dehydration (3%), vomiting (2%), and dyspnea (2%).

Erythropoietic therapies may increase the risk of cardiovascular events, including death. The higher risk of cardiovascular events may be associated with higher hemoglobin and/or higher rates of rise of hemoglobin. The hemoglobin level should be managed carefully, with a target not exceeding 120 g/L. **It is recommended that the dose of Aranesp® be decreased if the hemoglobin increase exceeds 10 g/L in any 2-week period, because of the association of excessive rate of rise of hemoglobin with these events (see Dose Adjustment).**

Like all growth factors, the possibility that Aranesp® can act as a growth factor for any tumour type cannot be excluded. After a median observation period of approximately 1 year, no statistically significant differences in time-to-progression (TTP) or overall survival (OS) were observed versus placebo.

†Aranesp® is covered by Alberta Health and Wellness effective July 1, 2005 by Special Authorization. Aranesp® will be considered for Pharmacare reimbursement by Manitoba Health on an individual prescriber/patient request basis as of September 15, 2005. Aranesp® will be reimbursed as of October 5, 2005 as a médicament d'exception on the Liste de médicaments du régime général du Québec for cancer patients with anemia.

*Note: Albumin formulation not currently available in Canada.

Product Monograph available upon request.



Amgen Canada, 6755 Mississauga Rd, Suite 400, Mississauga ON, L5N 7Y2 © 2005 Amgen. All rights reserved.

Aranesp®
(darbepoetin alfa)



2005 | Schedule-at-a-glance*

FRIDAY, OCTOBER 28

7:30am-11:30am

OPTIMAL HEMOGLOBIN MANAGEMENT WORKSHOP

Sponsored Pre-Conference Accredited Workshop (Ortho Biotech)

11:45am-1:45pm

TREATMENT OF A CANCER-RELATED COMPLICATION IN PALLIATIVE CARE: BOWEL OBSTRUCTION

Sponsored Pre Conference Accredited Workshop (Merck Frosst)

2pm-5:30pm

SATELLITE SYMPOSIUM

SURVIVAL ADVANCES IN TARGETED THERAPY FOR LUNG AND COLORECTAL CANCER

Sponsored Satellite Symposium (Roche)

5:45pm-10pm

SATELLITE SYMPOSIUM

VELCADE (BORTEZOMIB): AN INNOVATIVE THERAPEUTIC APPROACH IN THE TREATMENT OF MULTIPLE MYELOMA

Sponsored Satellite Symposium (Ortho Biotech)

SATURDAY, OCTOBER 29

6:30am-8am

SATELLITE SYMPOSIUM

PREVENTING CHEMOTHERAPY INDUCED EMESIS – NEW AGENTS AND GUIDELINES

Sponsored Satellite Symposium (Merck Frosst)

7:15am-8:15am (Ballrooms A & D)

NOPS CONTINENTAL BREAKFAST

8:15am-8:25am

WELCOME AND INTRODUCTION

8:30am-9am

PLENARY SESSION

HEALTH CARE FROM THE OTHER SIDE: ONE PATIENT'S PERSPECTIVE

9:05am-9:50am

PATIENT SAFETY - THE BIG PICTURE

9:55am-10:25am

ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER: WHAT IS THE STANDARD IN 2005?

10:25am-10:55am

BREAK

11am-11:45am

BREATHING NEW LIFE INTO LUNG CANCER: ADJUVANT CHEMOTHERAPY

11:50am-12:35pm

HANDLING CYTOTOXIC DRUGS - IS IT SAFER THAN FLYING IN A PLANE, DRIVING A CAR OR BUNGEE JUMPING?

12:35pm-1:05pm

LUNCH

1:05pm-2:05pm

CAPHO ANNUAL GENERAL MEETING

2:30pm-3:30pm

BREAKOUT #A1

DRUGGING THE HOT TARGETS - A PRIORITY OF THE IND PROGRAM AT NCIC CTG

BREAKOUT #A2

PATIENT SAFETY WORKSHOP ON FMEA (FAILURE, MODE, EFFECTS, ANALYSIS)

BREAKOUT #A3

THE GOOD, THE BAD AND THE UNKNOWN: A REVIEW OF THE EVIDENCE FOR HERBAL PRODUCTS

3:35pm-4:35pm

BREAKOUT #B1

WORKSHOP ON MUCOSITIS MANAGEMENT

BREAKOUT #B2

COMPATIBILITY AND STABILITY OF PARENTERAL CHEMOTHERAPY - IMPLICATIONS OF USP 797

BREAKOUT #B3

DRUG INTERACTION IN CHEMOTHERAPY - CYP, CYP EVERYWHERE, NOR ANY HINT OF WHAT TO DO

4:35pm-6:30pm

WINE AND CHEESE POSTER & EXHIBIT VIEWING

(Sponsored by Schering Canada)

SUNDAY, OCTOBER 30

7:00am-8:30am

SATELLITE SYMPOSIUM

SUPPORTIVE CARE – GROWTH FACTORS AND THE ROLE OF THE PHARMACIST

Sponsored Satellite Symposium (Amgen)

8am-9am

NOPS CONTINENTAL BREAKFAST

9:05am-9:20am

POSTER AWARD PRESENTATION

(Sponsored by Schering Canada)

9:25am-10:10am

TO ERR IS HUMAN, BUT DON'T BE TOO HUMAN - THE ROLE OF THE ONCOLOGY PHARMACIST IN ENSURING PATIENT SAFETY

10:15am-10:45am

BREAK

10:45am-11:10am

HYPERSENSITIVITY REACTIONS TO ANTINEOPLASTIC AGENTS - TO PRE-TREAT, RE-TREAT OR NOT?

11:15am-12:10pm

PANEL SESSION

THE TEAM APPROACH; PATIENT REPRESENTATIVE/PHARMACIST WORKING TOGETHER TO RESOLVE PATIENT CONCERNS

12:15pm-12:30pm

CLOSING REMARKS

1pm-2:30pm


EDUCATIONAL SESSION

THE ROLE OF AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER IN POSTMENOPAUSAL WOMEN

EDUCATIONAL SESSION

COMBINED MODALITY THERAPY FOR HIGH-RISK LOCALIZED ADENOCARCINOMA OF PROSTATE

*Please see daily schedule for room location.



** Moments like these are precious.*

With advances in cancer care, she can focus her energy on things that matter most. For more than a century, we have discovered some of the most important medicines that change our daily lives. Our research efforts span many spheres including **cancer**. Scientists at the Merck Frosst Centre for Therapeutic Research are committed to *discovering today for a better tomorrow*. As long as there is disease and suffering, we will continue our search.

Please visit our website at:
www.merckfrosst.com

 **MERCK FROSST**
*Discovering today
for a better tomorrow.*



FRIDAY, OCTOBER 28

2005 | FRIDAY, OCTOBER 28 SCHEDULE

8am-11:30am

PRE-CONFERENCE WORKSHOP (Location: Parksville)

OPTIMAL HEMOGLOBIN MANAGEMENT WORKSHOP

Sponsored Pre-Conference Accredited Workshop (Ortho Biotech)

Wendy Cheung BSc(Pharm) PharmD, Pierre Y. Cremieux PhD, Sean Hopkins, Pat Trozzo BSc(Chem) BSc(Pharm)

11:45am-1:45pm

PRE-CONFERENCE WORKSHOP (Location: Port McNeil)

TREATMENT OF A CANCER-RELATED COMPLICATION IN PALLIATIVE CARE: BOWEL OBSTRUCTION

Sponsored Pre Conference Accredited Workshop (Merck Frosst)

Kim Stefaniuk, Pat Trozzo BSc(Chem) BSc(Pharm)

2pm-5:30pm

SATELLITE SYMPOSIUM (Location: Parksville)

SURVIVAL ADVANCES IN TARGETED THERAPY FOR LUNG AND COLORECTAL CANCER

Sponsored Satellite Symposium (Roche)

Dr. Janessa Laskin, Dr. Amil Shah, Flay Charbonneau

5:45pm-10pm

SATELLITE SYMPOSIUM (Location: Junior Ballroom D)

VELCADE (BORTEZOMIB): AN INNOVATIVE THERAPEUTIC APPROACH IN THE TREATMENT OF MULTIPLE MYELOMA

Sponsored Satellite Symposium (Ortho Biotech)

Dr. Lynne Nakashima, Keith Stewart MD FRCP, Gabriel Gazze BPharm DPH, Joseph Mikhael MD Med FRCP

*At AstraZeneca,
we spend millions of dollars on R&D*

**ASTRAZENECA CANADA INC. IS PROUD TO BE A SPONSOR OF
THE 2005 NATIONAL ONCOLOGY PHARMACY SYMPOSIUM (NOPS)**

*every year in Canada
in our quest for new therapies and treatments.
We're constantly seeking better ways to treat and manage
illness, to enhance patients' quality of life,
and to keep our great healthcare system moving forward.
At AstraZeneca, that's our commitment to healthcare.*

www.astrazeneca.ca

The AstraZeneca logo is a trademark of
the AstraZeneca group of companies.

AstraZeneca 
life inspiring ideas



2005 | SATURDAY, OCTOBER 29 SCHEDULE

6:30am-8am

SATELLITE SYMPOSIUM (Location: Junior Ballrooms A & B)

PREVENTING CHEMOTHERAPY INDUCED EMESIS – NEW AGENTS AND GUIDELINES

Sponsored Satellite Symposium (Merck Frosst)

Dr. Celeste Lindley; Dr. David Warr

7:15am-8:15am

CONTINENTAL BREAKFAST FOR NOPS (Location: Grand Ballrooms A & D)

8:15am-8:25am

WELCOME AND INTRODUCTION (Location: Grand Ballrooms B & C)

8:30am-9am

PLENARY SESSION (Location: Grand Ballrooms B & C)

HEALTH CARE FROM THE OTHER SIDE: ONE PATIENT'S PERSPECTIVE

Susan R. Harris PhD PT, Professor, School of Rehabilitation Sciences, Faculty of Medicine – UBC

9:05am-9:50am

PATIENT SAFETY - THE BIG PICTURE (Location: Grand Ballrooms B & C)

Dr. Rob Robson, Director, Patient Safety, Winnipeg Regional Health Authority

9:55am-10:25am (Location: Grand Ballrooms B & C)

ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER: WHAT IS THE STANDARD IN 2005?

Sharlene Gill MD MPH FRCPC, Medical Oncologist, BC Cancer Agency

10:25am-10:55am

BREAK (Location: Grand Ballrooms A & D)

11am-11:45am (Location: Grand Ballrooms B & C)

BREATHING NEW LIFE INTO LUNG CANCER: ADJUVANT CHEMOTHERAPY

Thanh Vu BSc(Pharm) PharmD, Oncology Drug Information Specialist, BC Cancer Agency

11:50am-12:35pm (Location: Grand Ballrooms B & C)

HANDLING CYTOTOXIC DRUGS - IS IT SAFER THAN FLYING IN A PLANE, DRIVING A CAR OR BUNGEE JUMPING?

George Dranitsaris MPharm FCSHP, Consultant Pharmacist, Cancer Care Ontario

12:35pm-1:05pm

LUNCH (Location: Junior Ballrooms C & D)

1:05pm-2:05pm

CAPhO ANNUAL GENERAL MEETING (Location: Junior Ballrooms C & D)

2:30pm-3:30pm

BREAKOUT #A1 (Location: Junior Ballroom D)

DRUGGING THE HOT TARGETS - A PRIORITY OF THE IND PROGRAM AT NCIC CTG

Isabelle Gauthier PharmD, NCIC Fellow



2005 | SATURDAY, OCTOBER 29 SCHEDULE

BREAKOUT #A2 (Location: Junior Ballroom C)

PATIENT SAFETY WORKSHOP ON FMEA (FAILURE, MODE, EFFECTS, ANALYSIS)

Donna Woloschuk PharmD FCSHP MEd, Regional Pharmacy Manager (Education)
& Clinical Pharmacist – BMT, Winnipeg Regional Health Authority

2:30pm-3:30pm

BREAKOUT #A3 (Location: Junior Ballrooms A & B)

THE GOOD, THE BAD AND THE UNKNOWN: A REVIEW OF THE EVIDENCE FOR HERBAL PRODUCTS

Colleen Olson BSP, Senior Pharmacist, Saskatoon Cancer Centre

3:35pm-4:35pm

BREAKOUT #B1 (Location: Junior Ballroom D)

WORKSHOP ON MUCOSITIS MANAGEMENT

Anna Granic, Pharmacist, Grand River Hospital, Kitchener, ON

BREAKOUT #B2 (Location: Junior Ballroom C)

COMPATIBILITY AND STABILITY OF PARENTERAL CHEMOTHERAPY - IMPLICATIONS OF USP 797

Scott Walker MScPhm, Coordinator, Quality Control & Research Department of Pharmacy,
Sunnybrook & Women's Health Sciences Centre

BREAKOUT #B3 (Location: Junior Ballrooms A & B)

DRUG INTERACTION IN CHEMOTHERAPY - CYP, CYP EVERYWHERE, NOR ANY HINT OF WHAT TO DO

Carlo de Angelis PharmD, Clinical Coordinator, Pharmacy Department, Sunnybrook & Women's Health Sciences Centre

4:35pm-6:30pm (Location: Grand Ballrooms A & D)

WINE AND CHEESE

POSTER AND EXHIBIT VIEWING

(Sponsored by Schering Canada)




Introduction to Sopherion Therapeutics Canada


Established in late 2004 in Toronto Ontario, Sopherion Therapeutics Canada Inc. commercializes oncology and oncology-related products acquired and developed by Sopherion Therapeutics. Our scientists have unsurpassed expertise and domain knowledge in the discovery, development and clinical management of oncology products with a strong emphasis in the angiogenesis and metastasis fields

Sopherion Therapeutics first commercial product Myocet™, is a liposome-encapsulated doxorubicin-citrate complex developed to reduce the cardiac toxicity associated with conventional doxorubicin. Indicated for the 1st-line treatment of metastatic breast cancer in combination with cyclophosphamide it has received regulatory approval and will soon be available in Canada.

For company and product information contact 1- 866-497-8500



Bringing research to life



take no risk



TEVADAPTOR™
Setting new standards in safe handling of hazardous drugs




Our Company's Mission

Bristol-Myers Squibb Company's Mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products.




Bristol-Myers Squibb Canada



mayne pharma's R&D ● building on a solid structure

- Anti-infectives
- Hospital Injectables
- Injectable Antineoplastics
- Oral Antineoplastics



Mayne Pharma (Canada) Inc.
Montreal, Quebec, Canada
1 800 567 2855
Mayne is a trademark used under license.



2005 | SUNDAY, OCTOBER 30 SCHEDULE

6:30am-8am

SATELLITE SYMPOSIUM (Location: Junior Ballrooms A & B)

SUPPORTIVE CARE – GROWTH FACTORS AND THE ROLE OF THE PHARMACIST

Sponsored Satellite Symposium (Amgen)

Pat Trozzo BSc(Chem) BSc(Pharm), CancerCare Manitoba

8am-9am

CONTINENTAL BREAKFAST FOR NOPS (Location: Grand Ballrooms A & D)

9:05am-9:20am

POSTER AWARD PRESENTATION (Location: Grand Ballrooms B & C)

9:25am-10:10am (Location: Grand Ballrooms B & C)

TO ERR IS HUMAN, BUT DON'T BE TOO HUMAN - THE ROLE OF THE ONCOLOGY PHARMACIST IN ENSURING PATIENT SAFETY

Scott Edwards PharmD, Clinical Pharmacist, Newfoundland Cancer Treatment and Research Foundation

10:15am-10:45am

BREAK (Location: Grand Ballrooms A & D)

10:45am-11:10am (Location: Grand Ballrooms B & C)

HYPERSENSITIVITY REACTIONS TO ANTINEOPLASTIC AGENTS - TO PRE-TREAT, RE-TREAT OR NOT?

Carlo de Angelis PharmD, Clinical Coordinator, Pharmacy Department, Sunnybrook & Women's Health Sciences Centre

11:15am-12:10pm

PANEL SESSION (Location: Grand Ballrooms B & C)

THE TEAM APPROACH; PATIENT REPRESENTATIVE/PHARMACIST WORKING TOGETHER TO RESOLVE PATIENT CONCERNS

Roxanne Dobish BSc(Pharm), Assistant Director of Pharmacy, Alberta Cancer Board

Pat Trozzo BSc(Chem) BSc(Pharm) BCPS, Oncology Pharmacist/Site Manager, CancerCare Manitoba

Linda Tyre, Director, Patient Representative Services Northern Alberta

Alason Lorimer RN CPNC, Patient Representative, CancerCare Manitoba

12:15pm-12:30pm

CLOSING REMARKS (Location: Grand Ballrooms B & C)

1pm-2:30pm

EDUCATIONAL SESSION (Location: Junior Ballrooms A & B)

THE ROLE OF AROMATASE INHIBITORS IN THE TREATMENT OF BREAST CANCER IN POSTMENOPAUSAL WOMEN

Stephen Chia, Medical Oncologist, BC Cancer Agency, Vancouver Centre, Assistant Professor of Medicine, UBC

EDUCATIONAL SESSION (Location: Junior Ballrooms A & B)

COMBINED MODALITY THERAPY FOR HIGH-RISK LOCALIZED ADENOCARCINOMA OF PROSTATE

Michael McKenzie, Radiation Oncologist, BC Cancer Agency, Vancouver Centre, Clinical Associate Professor of the Division of Radiation Oncology, UBC





2005 | NOPS SPEAKER BIOGRAPHIES

CARLO DE ANGELIS PHARM D

Clinical Pharmacy Coordinator – Oncology, Sunnybrook and Women’s College Health Sciences Centre; Associate Professor, Clinical Pharmacy, Faculty of Pharmacy, University of Toronto; Pharmacy Owner, Panacea Pharmacy

Carlo De Angelis received his Bachelor of Pharmacy from the University of Toronto in 1981. He did his Hospital Pharmacy Residency at Sunnybrook and Women’s College Health Sciences Centre in 1982; and he received his Doctorate of Pharmacy from the State University of New York at Buffalo in 1984. Carlo specializes in cancer treatment symptom prevention and management; education and training in Oncology Pharmacy Practice; and, practice based research to support Oncology Clinical Pharmacy activities.

ROXANNE DOBISH | Assistant Director of Pharmacy, Alberta Cancer Board

Roxanne has a Bachelor of Science Degree in Pharmacy from the University of Alberta.

She has worked in oncology pharmacy for over 17 years in a variety of roles including staff pharmacist, involvement in the community cancer program implementation, and various management positions.

Roxanne’s areas of interest and specialization include medication error prevention, community cancer care, chemotherapy handling and certification, staff & student training, and policy and procedure development.

She is also involved in many multi-disciplinary committees and projects. Her presentation will highlight the interdisciplinary work between pharmacy and the patient representative

GEORGE DRANITSARIS MPHARM FCSHP | Consultant Pharmacist, Cancer Care Ontario

George Dranitsaris is an oncology research pharmacist with graduate training in biostatistics, health economics, decision analysis and clinical epidemiology. For 8 years, he was the Coordinator of Health Economics and Outcomes Research at Ontario Cancer Institute/Princess Margaret Hospital. He is currently a consultant to the pharmaceutical industry and public health care institutions such as Health Canada and Cancer Care Ontario. His areas of interest include the measurement of cost effective drug use and quality of life in the oncology setting, clinical trial design, the development and implementation clinical practice guidelines and the application of statistical modeling techniques for the evaluation of drug use in cancer patients. He has over 30 publications in peer-reviewed journals and holds several national and international awards. He is also past president of the Canadian Association of Pharmacists in Oncology and a Fellow with the Canadian Society of Hospital Pharmacists.

SCOTT EDWARDS PHARM D | Clinical Pharmacist, Newfoundland Cancer Treatment and Research Foundation

Scott Edwards graduated from Memorial University of Newfoundland with a BSc (Neuroscience) in 1994 and a BSc (Pharmacy) in 1997. In 2005 he graduated with a Doctorate of Pharmacy degree from the University of Washington. Scott is currently the clinical oncology pharmacist at the Dr. H. Bliss Murphy Cancer Center, an ambulatory medical oncology clinic that services the entire province of Newfoundland and Labrador. He is actively involved with numerous duties for Memorial University School of Pharmacy. Current research interest is acting as principal investigator for a randomized control trial studying seamless care in an outpatient medical oncology clinic.



2005 | NOPS SPEAKER BIOGRAPHIES

ISABELLE GAUTHIER PHARM D | NCIC Fellow

Isabelle Gauthier obtained her BSc (Pharm), and MSc from Laval University. She completed her PharmD degree followed by a specialty residency in hematology/oncology in New York. Isabelle has worked as a Clinical Professor at the University of Montreal Faculty of Pharmacy and, she also as a clinical pharmacy specialist in hemato/med oncology and the research pharmacist for the hematology/BMT team at the Ottawa Hospital.

In 2001, she joined the New Drug Development Program at the Ottawa Regional Cancer Center as the Clinical Research Coordinator. She is currently the CIHR/NCIC IND Fellow at NCIC CTG.

SHARLENE GILL BSC(PHARM) MD MPH FRCPC | British Columbia Cancer Agency, University of British Columbia

Sharlene Gill is an Assistant Professor of Medicine of Medical Oncology and an Associate Faculty Member of Gastroenterology at UBC. She received her BSc and MD from UBC followed by an Internal Medicine residency at the UBC Department of Medicine, and a Medical Oncology fellowship at the BC Cancer Agency. She completed a two-year postdoctoral clinical research fellowship in Gastrointestinal Oncology at the Mayo Clinic, and received a Master's of Public Health in Clinical Effectiveness from the Harvard School of Public Health. Sharlene is presently a GI Medical Oncologist at the Vancouver Cancer Centre and her research interests include phase II/III clinical trials, translational research collaborations and GI cancer outcomes evaluation.

ANNE GRANIC BSC(CHEM) BSC(PHARM) | Staff Pharmacist, Grand River Hospital

Anne received a Bachelor of Science Degree in Biology from the University of Western Ontario in London, Ontario, followed by a Bachelor of Science Degree in Pharmacy at the University of Alberta in Edmonton. Anne has been working as a staff pharmacist at Grand River Hospital for 15 years. She has been involved in several clinical programs, including cardiology, general medicine and palliative care, while continuing to work in pharmacy. For the past five years her focus has been in the Oncology program and Supportive Care. The past two years she has been very busy with the Regional Cancer Centre.

SUSAN R. HARRIS PHD | Professor, School of Rehabilitation Sciences, Faculty of Medicine, University of British Columbia

Susan Harris is a Professor in the School of Rehabilitation Sciences at UBC. Having experienced breast cancer twice (in 1994 and 1998), Dr. Harris has since become involved in breast cancer rehabilitation research as well as communication issues among persons living with cancer and their health care providers. Based on her own experiences, Susan has also become an advocate for improving patient navigation through the cancer care system and enhancing interdisciplinary care. She was the recipient of the UBC Alumni Association's Faculty Citation Community Service Award, and the Professional Achievement Award from the Canadian Breast Cancer Foundation.

ALASON LORIMER RN CPNC | Patient Representative, CancerCare Manitoba

Alason Lorimer is the Patient Representative at CancerCare Manitoba. Her role is to advocate for patients and their families throughout their cancer experience and to facilitate conflict resolution and problem solving.

She works collaboratively with all members of the care team to enhance communication between all parties. Ms. Lorimer offers an objective eye and a practical voice reducing tensions and moving people towards consensus and reconciliation. She graduated Winnipeg Health Sciences Centre School of Nursing and is a Canadian Certified Perioperative Nurse who specialized in women's health at the Health Sciences Centre in Winnipeg for 20 years. She is currently a student at the University of Manitoba.



2005 | NOPS SPEAKER BIOGRAPHIES

COLLEEN OLSON BA BSP | Senior Pharmacist, Saskatoon Cancer Centre

Colleen Olson graduated from the University of Saskatchewan. She currently is the Senior Pharmacist at the Saskatoon Cancer Centre. Colleen is a sectional lecturer at the College of Pharmacy at the University of Saskatchewan on Complementary and Alternative Medicine. She also is a speaker for the College of Physicians Continuing Medical Education on Herb and Complimentary Medicine.

DR. ROBERT ROBSON, DIRECTOR | Patient Safety, Winnipeg Regional Health Authority

Dr. Rob Robson is Chief Patient Safety Officer of the Winnipeg Regional Health Authority and is responsible for coordinating patient safety programs and initiatives throughout the region.

Dr. Robson is experienced in healthcare risk management, liability assessment, and litigation management issues and has participated in external reviews of organizations and facilities at federal, and provincial levels.

Rob has academic appointments in the Departments of Graduate Studies and Community Health Sciences of the University of Manitoba Faculty of Medicine.

Rob is a practicing specialist emergency physician. He is also a healthcare mediator and has worked for more than six years in this field.

PAT TROZZO BSC(CHEM) BSC(PHARM) BCPS | CancerCare, Manitoba

A career pharmacist, Pat graduated with his pharmacy degree from the University of Manitoba. He is currently an oncology pharmacist with the Saint Boniface Unit of CancerCare Manitoba. He has worked in oncology for nearly 15 years, in the areas of the treatment of gastrointestinal cancers and pain and symptom management. Very active in the management of disease and treatment-related adverse effects, Pat is a member of a multi-professional pain and symptom management team. He has worked on national initiatives to promote the role of the pharmacist in providing palliative and end-of-life care. Pat is also an educator of health care professionals in this field.

The University of Manitoba, Faculty of Pharmacy, has appointed Pat clinical assistant professor in the area of oncology and pain and symptom management.

LINDA TYRE | Director, Patient Representative Services Northern Alberta

Linda's nursing background lead her to human resource management and then to patient representative services. She has two levels of Patient Representative Certification from the Society of Healthcare Consumer Advocate (AHA). Linda trained in customer service, conflict resolution, negotiating skills, Volunteer Management Certification and has a certificate from U of A Faculty of Extension in Adult Education.

A former member of the faculty of GMCC in Voluntary Sector Management, Linda has written a course for distant learning in this field. As the CCI Patient Representative, she has trained employees and developed courses on customer service, communication skills, and telephone edict.

Linda was the first Canadian to receive the Ruth Ravich award from SHCA/American Hospitals Association, the highest award for a Patient Representative in N. America.



2005 | NOPS SPEAKER BIOGRAPHIES

THANH VU BSC PHARM D | Oncology Drug Information Specialist, British Columbia Cancer Agency

Thanh is currently the Oncology Drug Information Specialist at the BC Cancer Agency in Vancouver. She earned her undergraduate and Doctorate of Pharmacy degrees from the University of British Columbia. Thanh developed an interest in oncology early in her career, and worked at the Cross Cancer Institute in Edmonton prior to relocating to Vancouver. Thanh's clinical interests include the management of breast and lung malignancies.

Thanh is a member of several professional societies, including the Canadian College of Clinical Pharmacy and the International Association for the Study of Lung Cancer. Thanh serves as an Expert Reviewer for the Canadian Cancer Society.

SCOTT WALKER | Coordinator of Research & Quality Control Associate Professor, Faculty of Pharmacy, University of Toronto

Scott Walker is the Coordinator of Research and Quality Control in the Department of Pharmacy at Sunnybrook & Women's College Health Sciences Centre where he runs an analytical lab. Scott is also an Associate Professor in the Faculty of Pharmacy at the University of Toronto where he teaches pharmacokinetics. His research interests include drug stability in support of the IV-additive program, as well as the pharmacokinetics of drugs.

A fellow of the Canadian Society of Hospital Pharmacists, Scott has received more than 30 awards in the CSHP National Award. He served as an Associate Editor of CJHP and then is now the Editor.

DONNA WOLOSCHUK PHARM D FCSHP MED

Regional Pharmacy Manager (Education) & Clinical Pharmacist – BMT, Winnipeg Regional Health Authority

Donna has practiced as an oncology/BMT pharmacy clinician for over 20 years. She holds a Doctor of Pharmacy degree, a post-doctoral Specialized Residency in Oncology/BMT, and is also a certified Adult Educator. Donna also holds an Advanced Graduate Diploma in Distance Education (Technology) as well as a Master's Degree in Distance Education. She is an active member and Fellow of the Canadian Society of Hospital Pharmacists.

Donna's currently works for the Winnipeg Regional Health Authority which involves planning, implementing, evaluating and maintaining protocols, clinical practice guidelines and selected medication safety initiatives of the Manitoba Blood and Marrow Transplant Program and Winnipeg Regional Health Authority. She is also responsible for coordinating education and training initiatives of the WRHA's Pharmacy Program.



2006 | National Oncology Pharmacy Symposium

Join us for NOPS 2006 in Montreal, QC

October 13 – 15, 2006

Hyatt Regency Montreal

If you are interested in joining the organizing committee please
contact Martin Franco at mfranco.hmr@ssss.gouv.qc.ca

See you in 2006!

